. 2017 Apr 6;8(30):48922–48929. doi: 10.18632/oncotarget.16885

Table 1. Patient characteristics (N = 55).

	All		PORT		Non-PORT		p value
	No.	%	No.	%	No.	%	p value
Age, years	58(35–76)		58 (42–73)		59 (35–76)		0.391
≤ 60	34	61.8	10	71.4	24	58.5
> 60	21	38.2	4	28.6	17	41.5
Sex							0.975
Male	47	85.5	12	85.7	35	85.4
Female	8	14.5	2	14.3	6	14.6
Component							0.397
SCC	30	54.5	9	64.3	21	51.2
Non-SCC	25	45.5	5	35.7	20	48.8
Stage, AJCC 7^th							0.140
I-II	29	52.7	5	35.7	24	58.5
III	26	47.3	9	64.3	17	41.5
T stage, AJCC 7^th							0.826
T_1-2	34	61.8	9	64.3	25	61.0
T_3-4	21	38.2	5	35.7	16	39.0
N stage, AJCC 7^th							0.008*
N₀	23	41.8	1	7.2	22	53.7
N₁	14	25.5	5	35.7	9	21.9
N₂	18	32.7	8	57.1	10	24.4
Dissected lymph nodes(DLN)							0.702
≤ 17	29	52.7	8	57.1	21	51.2
> 17	26	47.3	6	42.9	20	48.8
Metastatic lymph nodes(MLN)							0.715
0–3	45	83.6	11	78.6	34	82.9
≥ 4	10	16.4	3	21.4	7	17.1
Metastatic lymph nodes(MLN)							0.960
≤ 10%	39	70.9	10	71.4	29	70.7
> 10%	16	29.1	4	28.6	12	28.3
Chemotherapy							0.016*
No	13	23.6	0	0.0	13	31.7
Yes	42	76.4	14	100.0	28	68.3
PCI							0.003*
No	50	91.9	10	71.4	40	97.6
Yes	5	9.1	4	28.6	1	2.4